CTLA-4 IHC staining provides critical insights into HCC immunobiology, prognostic stratification, and therapeutic targeting, but varies by cellular compartment (TILs vs. tumor cells), which complicates prognostic interpretation [140]. This evidence concerns the gene CTLA4 and neoplasm.